TTP Antibody (A-8): sc-374305

TTP Antibody (A-8) is a mouse monoclonal IgG2a kappa light chain antibody that detects TTP protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). TTP Antibody (A-8) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Tristetraprolin (TTP), also known as Nup475 and TIS11, is a crucial zinc-binding protein encoded by the immediate-early response gene Zfp-36, playing a significant role in the regulation of mRNA stability and inflammatory responses. TTP protein is primarily located in the cytoplasm, where TTP binds to AU-rich elements in the 3′ untranslated regions of target mRNAs, leading to their degradation. This localization is vital as TTP modulates the expression of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), thereby influencing immune responses and maintaining homeostasis. Studies have shown that TTP rapidly redistributes from the nucleus to the cytoplasm upon stimulation by mitogens, highlighting TTP′s dynamic role in cellular signaling. Knockout mice lacking TTP exhibit severe autoimmune conditions, including inflammatory arthritis and dermatitis, which can be mitigated by inhibiting TNF-α activity, underscoring TTP′s importance in regulating inflammation and potential as a therapeutic target in autoimmune diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TTP Antibody (A-8) References:

1. Sequence of a rat TIS11 cDNA, an immediate early gene induced by growth factors and phorbol esters.  |  Kaneda, N., et al. 1992. Gene. 118: 289-91. PMID: 1511903
2. The human TTP protein: sequence, alignment with related proteins, and chromosomal localization of the mouse and human genes.  |  Taylor, GA., et al. 1991. Nucleic Acids Res. 19: 3454. PMID: 2062660
3. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.  |  Coppo, P., et al. 2021. Blood. 137: 733-742. PMID: 33150928
4. Advances in the management of TTP.  |  Subhan, M. and Scully, M. 2022. Blood Rev. 55: 100945. PMID: 35216839
5. Clinical implications of tristetraprolin (TTP) modulation in the treatment of inflammatory diseases.  |  Snyder, BL. and Blackshear, PJ. 2022. Pharmacol Ther. 239: 108198. PMID: 35525391
6. Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP.  |  Kelen, K., et al. 2023. Int J Mol Sci. 24: PMID: 37762692
7. Cardiovascular Disease and Stroke in Immune TTP-Challenges and Opportunities.  |  Sukumar, S., et al. 2023. J Clin Med. 12: PMID: 37762903
8. TTP and pregnancy.  |  Gounder, P. and Scully, M. 2024. Br J Haematol. 205: 1288-1290. PMID: 39197429
9. Phosphorylation of tristetraprolin, a potential zinc finger transcription factor, by mitogen stimulation in intact cells and by mitogen-activated protein kinase in vitro.  |  Taylor, GA., et al. 1995. J Biol Chem. 270: 13341-7. PMID: 7768935
10. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency.  |  Taylor, GA., et al. 1996. Immunity. 4: 445-54. PMID: 8630730
11. Mitogens stimulate the rapid nuclear to cytosolic translocation of tristetraprolin, a potential zinc-finger transcription factor.  |  Taylor, GA., et al. 1996. Mol Endocrinol. 10: 140-6. PMID: 8825554

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-TTP Antibody (A-8) has 16 citations in a variety of scientific publications.

Primary antibodies like Anti-TTP Antibody (A-8) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

TTP Antibody (A-8) Specifications

Alternate Product Name: TTP

Product Clone Name: A-8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 166-285

Epitope Target: TTP

Epitope Species: human

Product Reactivity/Detection: TTP

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 16 citations in various scientific publications

Available Conjugates/Forms for TTP Antibody (A-8): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin